Rep. C. Scott Franklin Purchases Shares of Novo Nordisk A/S (NYSE:NVO)

Representative C. Scott Franklin (R-Florida) recently bought shares of Novo Nordisk A/S NYSE: NVO. In a filing disclosed on April 11th, the Representative disclosed that they had bought between $15,001 and $50,000 in Novo Nordisk A/S stock on March 27th. The trade occurred in the Representative's "FIDELITY TRADITIONAL IRA" account.

Representative C. Scott Franklin also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Novo Nordisk A/S NYSE: NVO on 3/27/2025.
• Purchased $50,001 - $100,000 in shares of Amazon.com NASDAQ: AMZN on 2/26/2025.
• Purchased $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 2/26/2025.
• Purchased $15,001 - $50,000 in shares of Lockheed Martin NYSE: LMT on 2/18/2025.
• Purchased $1,001 - $15,000 in shares of Lockheed Martin NYSE: LMT on 2/18/2025.
• Sold $1,000,001 - $5,000,000 in shares of The Baldwin Insurance Group NASDAQ: BWIN on 2/7/2025.
• Sold $15,001 - $50,000 in shares of The Baldwin Insurance Group NASDAQ: BWIN on 2/6/2025.
• Sold $50,001 - $100,000 in shares of Costco Wholesale NASDAQ: COST on 1/28/2025.
• Sold $1,001 - $15,000 in shares of Costco Wholesale NASDAQ: COST on 1/28/2025.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock traded down $4.89 during mid-day trading on Thursday, reaching $57.99. 32,159,601 shares of the stock were exchanged, compared to its average volume of 5,952,515. Novo Nordisk A/S has a fifty-two week low of $57.36 and a fifty-two week high of $148.15. The company has a market cap of $260.23 billion, a price-to-earnings ratio of 17.63, a price-to-earnings-growth ratio of 0.90 and a beta of 0.61. The firm has a 50-day simple moving average of $76.55 and a 200 day simple moving average of $92.55. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, sell-side analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which was paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st were paid a $0.7874 dividend. This represents a dividend yield of 1.2%. The ex-dividend date was Monday, March 31st. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. Novo Nordisk A/S's payout ratio is currently 49.54%.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on NVO shares. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. StockNews.com lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a report on Tuesday. Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. BMO Capital Markets reissued a "market perform" rating and issued a $64.00 target price (down from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday. Finally, Stifel Nicolaus lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $135.00.

Hedge Funds Weigh In On Novo Nordisk A/S

Several institutional investors and hedge funds have recently made changes to their positions in NVO. Center for Financial Planning Inc. increased its holdings in shares of Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after acquiring an additional 123 shares in the last quarter. Strategic Investment Solutions Inc. IL raised its holdings in Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after buying an additional 300 shares during the period. Park Square Financial Group LLC bought a new position in Novo Nordisk A/S in the fourth quarter valued at approximately $29,000. Transce3nd LLC acquired a new position in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $33,000. Finally, CX Institutional acquired a new stake in shares of Novo Nordisk A/S during the first quarter worth $36,000. Institutional investors and hedge funds own 11.54% of the company's stock.

About Representative Franklin

Scott Franklin (Republican Party) is a member of the U.S. House, representing Florida's 18th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Franklin (Republican Party) is running for re-election to the U.S. House to represent Florida's 18th Congressional District. He declared candidacy for the 2026 election. Scott Franklin was born in Thomaston, Georgia. Franklin graduated from Lakeland High School. He served in the U.S. Navy from 1986 to 2000 and the U.S. Navy Reserve from 2000 to 2012. Franklin earned a B.S. from the United States Naval Academy in 1986 and an M.B.A. from Embry-Riddle Aeronautical University in 1994. Franklin's career experience includes owning an insurance agency and working as a naval aviator with the U.S. Navy.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.